Novel Drug for HER2-Mutant Lung Cancer Wins FDA Approval

(MedPage Today) — The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations.
Approval of the tyrosine…